Prevalence and treatment of spasticity reported by multiple sclerosis patients

Multiple Sclerosis

Volumn 10, Issue 5, 2004, Pages 589-595

  Rizzo, Marco A ^a   Hadjimichael, O C ^a   Preiningerova, J ^a   Vollmer, T L ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Epidemiology; Intrathecal baclofen; Multiple sclerosis; Prevalence; Quality of life; Spasticity; Treatment

Indexed keywords

BACLOFEN; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; GABAPENTIN; IBUPROFEN; PARACETAMOL; SPASMOLYTIC AGENT; TIZANIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DISEASE SEVERITY; FATIGUE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE STIFFNESS; MYALGIA; PHYSIOTHERAPY; PREVALENCE; QUALITY OF LIFE; SCORING SYSTEM; SPASTICITY;

ADMINISTRATION, ORAL; ADULT; BACLOFEN; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PREVALENCE; QUALITY OF LIFE; REGISTRIES;

EID: 4444288689     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1085oa     Document Type: Article

References (12)

1. Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair 2003; 17: 66-70.
2. Kesselring J, Thompson AJ. Spasticity, ataxia and fatigue in multiple sclerosis. Baillieres Clin Neurol 1997; 6: 429-45.
3. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2001; 4: CD001332.
4. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003; 7: 124.
5. Paisley S, Beard S, Hunn A, Wight J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Multiple Sclerosis 2002; 8: 319-29.
6. Vollmer T, Hadjimichael O, Ni W. Development and uses of the NARCOMS Registry. Consortium of Multiple Sclerosis Centers Annual Meeting. Halifax; June 22, 2000.
7. Hohol M, Orav E, Weiner H. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995; 5: 251-55.
8. Schwartz CE, Vollmer T, Lee H. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 1999; 2: 63-71.
9. Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales: a manual for users of Version 1, second Edition. Lincoln, RI: QualityMetric, Inc., 2001.
10. SAS Institute Inc. SAS Language and Procedures. Cary, NC: SAS, 1997.
11. Minden SL, Marder WD, Harrold LN, Dor A. Multiple sclerosis: a statistical portrait. Cambridge, MA: National MS Society. Abt Associates, 1993.
12. Collins JG. Prevalence of selected chronic conditions, United States, 1986-1988. National Center for Health Statistics. Vital Health Stat 1993; 10: 1-94.